Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Revenue (2016 - 2025)

Historic Revenue for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $13.4 million.

  • Voyager Therapeutics' Revenue fell 4559.26% to $13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.4 million, marking a year-over-year decrease of 8084.44%. This contributed to the annual value of $80.0 million for FY2024, which is 6800.06% down from last year.
  • Per Voyager Therapeutics' latest filing, its Revenue stood at $13.4 million for Q3 2025, which was down 4559.26% from $5.2 million recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Revenue ranged from a high of $150.5 million in Q1 2023 and a low of -$1.5 million during Q4 2022
  • In the last 5 years, Voyager Therapeutics' Revenue had a median value of $6.5 million in 2025 and averaged $22.8 million.
  • Its Revenue has fluctuated over the past 5 years, first crashed by 10552.13% in 2022, then skyrocketed by 2276930.09% in 2023.
  • Quarter analysis of 5 years shows Voyager Therapeutics' Revenue stood at $28.1 million in 2021, then plummeted by 105.52% to -$1.5 million in 2022, then skyrocketed by 5910.39% to $90.1 million in 2023, then tumbled by 93.03% to $6.3 million in 2024, then skyrocketed by 113.44% to $13.4 million in 2025.
  • Its last three reported values are $13.4 million in Q3 2025, $5.2 million for Q2 2025, and $6.5 million during Q1 2025.